What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta...
Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength...
Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered...
Unfortunately, there is as much misinformation as good information about the unusual subtype of lung cancer known as bronchioloalveolar carcinoma (BAC...
Bronchioloalveolar carcinoma (BAC), also known as adenocarcinoma in situ, is an unusual subtype of lung cancer with its own appearance under a...
Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over...
Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer...
Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the...
Dr. Leighl, lung cancer expert from Princess Margaret Hospital in Toronto, continued her summary of the leading highlights in lung cancer from 2012...
Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to...
Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.
[powerpress]
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.
[powerpress]
Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.
[powerpress]
Dr. Cathy Pietanza of Memorial Sloan Kettering talks about the role of PARP inhibitors in the treatment of small cell lung cancer. February 2014.
[powerpress]
Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.
[powerpress]
Dr. Edward Garon discusses what researchers are learning about MK-3475, an immune therapy treatment currently in clinical trial. February 2014.
[powerpress]
Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.
[powerpress]
Here's a text-heavy but still brief summary "slidedoc" of what I would consider to be the core principles of managing locally advanced, or stage III, non-small cell lung cancer (NSCLC). This is a heterogeneous population that accounts for about 40% of the patients newly diagnosed with NSCLC, with some having far more extensive and bulky disease than others. Though individual treatment recommendations should be made by the physicians directly reviewing the details of a patient's case, the key principles still govern the overall plan.
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses whether PARP treatments can be taken alone or if they must be taken with other drugs. February 2014.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.